{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:15:37Z","timestamp":1791908137855,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04150-2","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T11:05:55Z","timestamp":1764241555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictive molecular alterations of prostate cancer brain metastases based on a companion diagnostic assay"],"prefix":"10.1007","volume":"16","author":[{"given":"Antonio","family":"Rodr\u00edguez-Calero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Benjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Maletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilara Akhoundova","family":"Sanoyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zoche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Moch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"4150_CR1","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci. 2019;116:11428\u201336.","journal-title":"Proc Natl Acad Sci"},{"key":"4150_CR2","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","volume":"50","author":"J Armenia","year":"2018","unstructured":"Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, et al. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018;50:645\u201351.","journal-title":"Nat Genet"},{"key":"4150_CR3","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","volume":"63","author":"H Beltran","year":"2013","unstructured":"Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, et al. Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol. 2013;63:920\u20136.","journal-title":"Eur Urol"},{"key":"4150_CR4","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med. 2015;373:1697\u2013708.","journal-title":"N Engl J Med"},{"key":"4150_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, Sarkar ND, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443\u201353.","journal-title":"N Engl J Med"},{"key":"4150_CR6","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"D Robinson","year":"2015","unstructured":"Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215\u201328.","journal-title":"Cell"},{"key":"4150_CR7","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091\u2013102.","journal-title":"N Engl J Med"},{"key":"4150_CR8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3389\/fonc.2019.00801","volume":"9","author":"MA Rice","year":"2019","unstructured":"Rice MA, Malhotra SV, Stoyanova T. Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer. Front Oncol. 2019;9:801.","journal-title":"Front Oncol"},{"key":"4150_CR9","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1038\/s41467-022-30003-5","volume":"13","author":"A Rodriguez-Calero","year":"2022","unstructured":"Rodriguez-Calero A, Gallon J, Akhoundova D, Maletti S, Ferguson A, Cyrta J, et al. Alterations in homologous recombination repair genes in prostate cancer brain metastases. Nat Commun. 2022;13:2400.","journal-title":"Nat Commun"},{"key":"4150_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/2056-4538.12362","volume":"10","author":"M Forster-Sack","year":"2024","unstructured":"Forster-Sack M, Zoche M, Pestalozzi B, Witzel I, Schwarz EI, Herzig JJ, et al. ERBB2-amplified lobular breast carcinoma exhibits concomitant CDK12 co-amplification associated with poor prognostic features. J Pathol Clin Res. 2024;10:e12362.","journal-title":"J Pathol Clin Res"},{"key":"4150_CR11","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.1038\/s41598-025-85846-x","volume":"15","author":"H Niitsu","year":"2025","unstructured":"Niitsu H, Nakahara H, Ishida K, Kaneko Y, Hayes CN, Arihiro K, et al. Real-world data analysis for factors influencing the quality check status in FoundationOne CDx cancer genomic profiling tests. Sci Rep. 2025;15:5167.","journal-title":"Sci Rep"},{"key":"4150_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264138","volume":"17","author":"CA Milbury","year":"2022","unstructured":"Milbury CA, Creeden J, Yip WK, Smith DL, Pattani V, Maxwell K, et al. Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors. PLoS ONE. 2022;17:e0264138.","journal-title":"PLoS ONE"},{"key":"4150_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731\u20139.","journal-title":"N Engl J Med"},{"key":"4150_CR14","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1002\/onco.13639","volume":"26","author":"M Takeda","year":"2021","unstructured":"Takeda M, Takahama T, Sakai K, Shimizu S, Watanabe S, Kawakami H, et al. Clinical application of the FoundationOne CDx assay to therapeutic decision-making for patients with advanced solid tumors. Oncologist. 2021;26:e588\u201396.","journal-title":"Oncologist"},{"key":"4150_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000675","volume":"5","author":"V De Falco","year":"2020","unstructured":"De Falco V, Poliero L, Vitiello PP, Ciardiello D, Vitale P, Zanaletti N, et al. Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania \u2018Luigi Vanvitelli.\u2019 ESMO Open. 2020;5:e000675.","journal-title":"ESMO Open"},{"key":"4150_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/jmp4030014","volume":"4","author":"R Pinto","year":"2023","unstructured":"Pinto R, Schmitt F. A real-world study reporting the use of Foundation Medicine\u00ae testing in Portugal. J Mol Pathol. 2023;4:156\u201365.","journal-title":"J Mol Pathol"},{"key":"4150_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0266112","volume":"17","author":"Y Aoyagi","year":"2022","unstructured":"Aoyagi Y, Kano Y, Tohyama K, Matsudera S, Kumaki Y, Takahashi K, et al. Clinical utility of comprehensive genomic profiling in Japan: result of PROFILE-F study. PLoS ONE. 2022;17:e0266112.","journal-title":"PLoS ONE"},{"key":"4150_CR18","doi-asserted-by":"publisher","first-page":"15304","DOI":"10.1002\/cam4.6175","volume":"12","author":"K Yang","year":"2023","unstructured":"Yang K, Yu W, Liu H, Lou F, Cao S, Wang H, et al. Mutational pattern off homologous recombination repair (HRR)-related genes in upper tract urothelial carcinoma. Cancer Med. 2023;12:15304\u201316.","journal-title":"Cancer Med"},{"key":"4150_CR19","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1002\/cam4.5333","volume":"12","author":"H Uemura","year":"2023","unstructured":"Uemura H, Oya M, Kamoto T, Sugimoto M, Shinozaki K, Morita K, et al. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: the multi-institutional observational ZENSHIN study. Cancer Med. 2023;12:5265\u201374.","journal-title":"Cancer Med"},{"key":"4150_CR20","doi-asserted-by":"publisher","first-page":"22370","DOI":"10.1002\/cam4.6725","volume":"12","author":"J Chen","year":"2023","unstructured":"Chen J, Tang Y, Liu H, Sun G, Liu H, Zhao J, et al. The mutational pattern of homologous recombination repair genes in urothelial carcinoma and its correlation with immunotherapeutic response. Cancer Med. 2023;12:22370\u201380.","journal-title":"Cancer Med"},{"key":"4150_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or physician\u2019s choice in metastatic prostate cancer. N Engl J Med. 2023;388:719\u201332.","journal-title":"N Engl J Med"},{"key":"4150_CR22","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1094\u2013108.","journal-title":"Lancet Oncol"},{"key":"4150_CR23","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41:3339\u201351.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4150_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet Lond Engl. 2023;402:291\u2013303.","journal-title":"Lancet Lond Engl"},{"key":"4150_CR25","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.trsl.2022.11.009","volume":"255","author":"YA Jakubek","year":"2023","unstructured":"Jakubek YA, Reiner AP, Honigberg MC. Risk factors for clonal hematopoiesis of indeterminate potential and mosaic chromosomal alterations. Transl Res. 2023;255:171\u201380.","journal-title":"Transl Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04150-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04150-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04150-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T02:37:37Z","timestamp":1767062257000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04150-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4150"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04150-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"30 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All analyses followed protocols approved by the Ethical Committee Bern (Project ID: 2019\u201300328). The study was performed in accordance with the Declaration of Helsinki. Patients qualified for inclusion in this study if they were informed about the conditions in the general consent and written general consent was signed. Inclusion also applied for patients whose prostate cancer tissue was collected prior to official use of general consent, and\/or no written or documented verbal refusal was available at any time (Human Research Act, HRA, Swiss Confederation; Art. 34).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"According to the above mentioned ethical approval, we may publish the results after completion of the research project. Publications will not contain any references to specific individuals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Costs of FoundationOne\u00aeCDx analyses were covered by Roche Pharma (Schweiz) AG, Basel, Switzerland. D.A. has received honoraria for lectures, presentations or advisory boards from BMS, Janssen, and Bayer; conference\/travel support from Janssen, Ipsen, and Bayer. H.M. has received research funding to University Zurich from F. Hoffmann-La Roche Ltd., and personal consultancy fees as advisory board member from Astra Zeneca and Stemline Therapeutics, Bayer, Amgen, Astella, MSD. M.A.R. is a co-inventor on patents in the area for diagnosis and therapy in prostate cancer for ETS fusions (University of Michigan and the Brigham and Women\u2019s Hospital), SPOP mutations (Cornell University), and EZH2 (University of Michigan). The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2328"}}